3/11
08:15 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/10
04:12 pm
chrs
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
3/3
08:30 am
chrs
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
Medium
Report
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
2/24
09:08 am
chrs
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
Medium
Report
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
1/23
08:02 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
1/22
07:34 am
chrs
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
Low
Report
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
1/22
07:00 am
chrs
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Medium
Report
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
1/8
08:00 am
chrs
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/19
01:32 pm
chrs
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
12/18
08:38 am
chrs
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
Medium
Report
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
12/18
08:30 am
chrs
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Medium
Report
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
12/18
08:14 am
chrs
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]
Medium
Report
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]